Treatment of Maxillary Sinus Carcinoma: Clinical Results Using the Kitasato Modality

The conventional therapeutic regimen for maxillary sinus carcinoma consists of dissection of the maxilla, full-dose irradiation and extensive chemotherapy. However, the results obtained with this treatment are often poor. Even when patients recover, their quality of life is significantly reduced as...

Full description

Saved in:
Bibliographic Details
Published in:Acta oto-laryngologica 2002, Vol.122 (4), p.15-19
Main Authors: Yao, Kazuo, Takahashi, Hiroomi, Inagi, Katsuhide, Nakayama, Meijin, Makoshi, Tomohiro, Nagai, Hiromi, Okamoto, Makito
Format: Article
Language:English
Subjects:
Arterial
Cellular
Chemotherapy
Combined
Dissection
Immunity
Intra
Maxillectomy
Modified
Neck
Partial
Radiation
Therapy
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The conventional therapeutic regimen for maxillary sinus carcinoma consists of dissection of the maxilla, full-dose irradiation and extensive chemotherapy. However, the results obtained with this treatment are often poor. Even when patients recover, their quality of life is significantly reduced as a result of deformity of facial structures and swallowing and articulation dysfunctions. A retrospective analysis of 68 patients with maxillary sinus carcinoma treated with the Kitasato modality between 1975 and 1999 was conducted. All patients underwent pergingival maxillary sinus surgery combined with pre- and postoperative irradiation therapy with standardized total doses of 16 Gy; the postoperative irradiation was given in combination with regional intra-arterial infusion chemotherapy administered via the superficial temporal artery. All visible tumor lesions were removed where possible in order to preserve or facilitate cellular immunity after surgery. The cumulative 5-year survival rates were 85.7% for Stage II patients, 88.1% for Stage III, 76.6% for Stage IVA and 75.0% for Stage IVB.
ISSN:0001-6489
1651-2251
DOI:10.1080/000164802760057509